Study S000519

Pharmacogenetics of Response to GLP1R Agonists

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05071898
Acronym: PORT
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: RECRUITING
Enrollment: 600
Start: 2022-04-11
Primary completion: 2027-04-30
Lead sponsor: University of Maryland, Baltimore
Conditions: Obesity; Diabetes Type 2
Interventions: DRUG:Semaglutide Pen Injector [Ozempic]
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

First phase insulin secretion [Measured both at baseline and after completing 6 weeks of semaglutide therapy]
Second phase insulin secretion [Measured both at baseline and after completing 6 weeks of semaglutide therapy]
Rate of glucose disappearance [Measured both at baseline and after completing 6 weeks of semaglutide therapy]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0005987	Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness. Taylor SI, medRxiv : the preprint server for health sciences	2023	Other	PMID 36993363 DOI	cites ClinicalTrials.gov:NCT05071898